Blood test may forecast heart valve risks
NCT ID NCT04571372
First seen Jul 13, 2026 · Last updated Jul 14, 2026 · Updated 1 time
Summary
This study looks at whether a substance in the blood called suPAR can help predict serious health events in people with severe aortic stenosis or regurgitation. Researchers will measure suPAR levels and track participants for two years to see if higher levels are linked to death, heart-related death, or worsening kidney function. The goal is to find a simple blood test that could flag those at higher risk.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If suPAR levels are linked to worse outcomes, this could help doctors identify high-risk patients earlier.
- What could go wrong
- This is an observational study, not a treatment trial. It may find no strong link, and results may not change care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SEVERE AORTIC STENOSIS OR SEVERE AORTIC REGURGITATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine
Seoul, South Korea